1. Pink Sheet
  2. >>Market Access

Orphan Drug Pricing Heading To Negotiating Table in US?

 
• By Cathy Kelly

The Institute for Clinical and Economic Review is launching an initiative to adapt its value assessment approach to orphan and ultra-orphan drugs, including a possible consideration of what should be a fair return on investment for manufacturers.

Handshake of businessmen

US payers are seeking tools for managing orphan drug costs in a way that more explicitly ties pricing to value. This is relatively uncharted territory in the US, where the prices set by manufacturers for drugs targeting few patients have generally been considered non-negotiable.

Cost pressures on payers are growing, driven by a significant acceleration in orphan drug approvals, as well as increasing prices...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

Second-Most Favored Nation? CMS Clarifies Medicaid Price Benchmark In GENEROUS Model

 
• By Cathy Kelly

Demonstration could bring unprecedented transparency into international net prices, at least to CMS.

UK Needs Specialist Scientific Knowledge To Stay Competitive Post-Brexit, AstraZeneca Says

 
• By Eliza Slawther

A senior AstraZeneca executive says the UK MHRA must develop specialist expertise and create incentives for companies to file marketing authorizations nationally if it wants to stand out to strategic decision-makers.

Brazil To Fix Regulatory Reliance Shortfalls & Speed Up Approvals

 
• By Francesca Bruce

Regulatory reliance processes for drug registration and clinical trial application approvals in Brazil have not met their “full potential,” says Brazil’s medicines regulator.

EU Moment Of Truth For Teplizumab, Etuvetidigene Autotemcel & Other Drugs

 
• By Neena Brizmohun

The sponsors of a number of drugs could this week learn whether the European Medicines Agency will recommend in favor of approving their products. And while teplizumab was approved in the US in 2022, Sanofi told the Pink Sheet why it waited to submit the drug for regulatory review in the EU.

More from Pink Sheet

‘Why We Would Do It Again’ – Gilead & Roche On Pioneering Global Initiative For Manufacturing Change

Gilead and Roche reflect on their experiences with a global initiative that delivered aligned regulatory decisions through joint hybrid inspections and synchronized review of post-approval changes.

Novel Alzheimer’s Drug Blarcamesine Scheduled For High-Stakes EMA Oral Explanation

 
• By Neena Brizmohun

The EMA has scheduled oral explanation meetings this week for Anavex’s blarcamesine and three other products that are nearing the end of the regulatory review cycle. These meetings usually represent the final chance for sponsors to persuade the agency that their product merits approval.

Sponsored by

The British Pharmacopoeia: Setting standards that are trusted worldwide

In this exclusive article with Peter Crowley, Secretary and Scientific Director of the BP Commission, you’ll discover how the BP is preparing for its landmark 2026 edition while strengthening its influence as a global bridge between science, regulation, and industry.